Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ERNA-201
- Development stage
- Preclinical
- Lead developer
- Ernexa Therapeutics
- Modality
- Mesenchymal Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies, iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
ERNA-201 is a synthetic, off-the-shelf cell therapy product comprised of induced pluripotent stem cell (iPSC)-derived mesenchymal stem cells (iMSCs), engineered specifically to target inflammation and treat autoimmune diseases such as rheumatoid arthritis. ERNA-201 is designed to re-polarize macrophages in the synovial microenvironment towards an anti-inflammatory and regenerative state, and exhibits enhanced anti-inflammatory functionality through features such as uniform clonality, high proliferative capacity, increased immunosuppressive IDO-1 expression, reduced immunogenicity, and secretion of the immunoregulatory cytokine IL-10. This therapy aims to calm overactive immune cells and provide durable, precise targeting to sites of inflammation, potentially offering disease-modifying effects superior to traditional native MSC therapies[1][3][5][6][7][9][11][14][15].
- Brand names
- ERNA-201ERNA201ERNA 201
- Other names
- ERNA-201ERNA201ERNA 201
02
Targets
IL10RA (Interleukin-10 Receptor)
Beyond the preview
Go deeper on ERNA-201.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ERNA-201.